Vienna - Delayed Quote • EUR Galapagos NV (GLPG.VI) Follow Compare 22.18 -0.08 (-0.36%) At close: January 31 at 3:30:34 PM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for GLPG.VI 1D 5D -1.86% 1M -15.60% 3M -15.86% 6M -12.54% YTD -15.60% 1Y -37.47% 5Y -89.19% All -74.54% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: GLPG.VI View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40% Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25% ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023) Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ... Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Related Tickers ALEMS.BR European Medical Solutions 6.60 +7.32% BIOS.BR BioSenic S.A. 0.0036 0.00% HYL.BR Hyloris Pharmaceuticals SA 5.38 +0.75% TUB.BR Financière de Tubize SA 152.80 -0.26% ARGX.BR argenx SE 643.00 +1.26% UCB.BR UCB SA 188.20 -0.61%